A2 Biotherapeutics develops Tmod™, a precision-targeting T cell therapy platform that distinguishes solid tumors from normal cells by exploiting specific gene losses unique to cancer cells. This approach addresses the challenge of effective treatment for solid tumors while minimizing damage to healthy tissue.
Funding
$352.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors pose a significant challenge in cancer treatment due to the difficulty in distinguishing them from normal, healthy cells. Traditional cancer therapies often damage healthy tissue, leading to severe side effects and limiting treatment effectiveness. The lack of precision in targeting solid tumors hinders the development of more effective and less toxic cancer treatments.
Solution
A2 Biotherapeutics is developing the Tmod™ platform, a precision-targeting T cell therapy designed to differentiate solid tumors from normal cells by exploiting specific gene losses unique to cancer cells. This approach aims to direct the immune system to attack tumors while minimizing harm to healthy tissue. The Tmod™ platform integrates multiple signals to overcome the limitations of conventional single-target therapies. A2 Bio's platform is designed to enable a broad pipeline of both autologous and allogeneic cell products that access a large array of unexploited therapeutic targets, including targets previously constrained by toxicity.
Target Audience
The primary target audience includes patients with solid tumors and the medical professionals (oncologists) who treat them, as well as clinical researchers focused on developing novel cancer therapies.
Features
- Tmod™ precision-targeting cell therapy platform distinguishes tumor from normal cells.
- Exploits the loss of genetic material in cancer cells.
- Modular and flexible platform designed to enable a broad pipeline of both autologous and allogeneic cell products.
- Targets previously constrained by toxicity.
- In-house cGMP autologous & allogeneic manufacturing capability.